Drugs such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are making massive profits, and also have decent odds of preventing many obesity-induced (and also diabetes-induced) diseases
Okay, they also have side effects, and it is possible the disease burden caused by the side effects may (in the long-run) turn out to be worse than the disease burden they prevent. But, while that's a possibility, it is only a possibility, a possibility which could easily not come pass to
And even if some of those drugs turn out to have unacceptable side effects in the long-run, there are other drugs in that class in the pipeline which might avoid those side effects, in which case the profits will shift to those
This is very unlikely to happen. This isn't like other obesity drugs that were first in class, glp-1 agonists have been around a long time and have a great safety record.
The NHS costs half as much per captia as medicare, medicaid, etc and provides universal coverage.
That isn't it. It's simply theft.